Emily Bodnar
Stock Analyst at HC Wainwright & Co.
(1.16)
# 1,554
Out of 4,412 analysts
121
Total ratings
28.57%
Success rate
-14.98%
Average return
Main Sectors:
Top Industries:
22 Stocks
| Stock | Action | Price Target | Current | Upside | Ratings | Updated | |
|---|---|---|---|---|---|---|---|
| PPBT Purple Biotech | Reiterates: Buy | $10 | $0.49 | +1,940.82% | 9 | Apr 26, 2024 | |
| ACRV Acrivon Therapeutics | Reiterates: Buy | $20 | $8.46 | +136.41% | 6 | Apr 25, 2024 | |
| LTRN Lantern Pharma | Reiterates: Neutral | n/a | $5.50 | - | 1 | Apr 25, 2024 | |
| CNTB Connect Biopharma Holdings | Maintains: Buy | $7 → $8 | $1.34 | +497.01% | 2 | Apr 17, 2024 | |
| ATOS Atossa Therapeutics | Reiterates: Buy | $4 | $1.53 | +161.44% | 3 | Apr 16, 2024 | |
| RNAZ TransCode Therapeutics | Reiterates: Buy | $3 | $0.55 | +445.55% | 6 | Apr 16, 2024 | |
| GNLX Genelux | Maintains: Buy | $35 → $32 | $3.40 | +841.18% | 2 | Apr 2, 2024 | |
| IMNN Imunon | Maintains: Buy | $12 → $13 | $1.44 | +802.78% | 5 | Apr 1, 2024 | |
| SLRN Acelyrin | Reiterates: Buy | $28 | $4.24 | +560.38% | 6 | Apr 1, 2024 | |
| FEMY Femasys | Maintains: Buy | $10 → $12 | $1.27 | +844.88% | 7 | Apr 1, 2024 | |
| NVCR NovoCure | Maintains: Neutral | $22 → $24 | $12.64 | +89.95% | 9 | Mar 27, 2024 | |
| NKTX Nkarta | Maintains: Buy | $20 → $22 | $6.87 | +220.23% | 9 | Mar 25, 2024 | |
| NXTC NextCure | Maintains: Buy | $5 → $8 | $1.35 | +492.59% | 2 | Mar 22, 2024 | |
| CNTX Context Therapeutics | Maintains: Buy | $5 → $4 | $1.41 | +183.67% | 6 | Mar 21, 2024 | |
| INKT MiNK Therapeutics | Maintains: Buy | $10 → $9 | $0.93 | +870.35% | 6 | Mar 21, 2024 | |
| AGEN Agenus | Maintains: Buy | $160 | $11.69 | +1,268.69% | 5 | Mar 14, 2024 | |
| OLMA Olema Pharmaceuticals | Maintains: Buy | $28 → $25 | $9.95 | +151.26% | 8 | Mar 12, 2024 | |
| IOBT IO Biotech | Reiterates: Buy | $8 | $1.42 | +463.38% | 5 | Mar 6, 2024 | |
| SANA Sana Biotechnology | Reiterates: Buy | $12 | $8.72 | +37.61% | 3 | Mar 1, 2024 | |
| ACLX Arcellx | Maintains: Buy | $60 → $82 | $51.92 | +57.94% | 8 | Feb 29, 2024 | |
| BCTX BriaCell Therapeutics | Reiterates: Buy | $18 | $2.23 | +707.17% | 5 | Dec 28, 2023 | |
| VTYX Ventyx Biosciences | Downgrades: Neutral | n/a | $3.93 | - | 8 | Nov 7, 2023 |
Purple Biotech
Apr 26, 2024
Reiterates: Buy
Price Target: $10
Current: $0.49
Upside: +1,940.82%
Acrivon Therapeutics
Apr 25, 2024
Reiterates: Buy
Price Target: $20
Current: $8.46
Upside: +136.41%
Lantern Pharma
Apr 25, 2024
Reiterates: Neutral
Price Target: n/a
Current: $5.50
Upside: -
Connect Biopharma Holdings
Apr 17, 2024
Maintains: Buy
Price Target: $7 → $8
Current: $1.34
Upside: +497.01%
Atossa Therapeutics
Apr 16, 2024
Reiterates: Buy
Price Target: $4
Current: $1.53
Upside: +161.44%
TransCode Therapeutics
Apr 16, 2024
Reiterates: Buy
Price Target: $3
Current: $0.55
Upside: +445.55%
Genelux
Apr 2, 2024
Maintains: Buy
Price Target: $35 → $32
Current: $3.40
Upside: +841.18%
Imunon
Apr 1, 2024
Maintains: Buy
Price Target: $12 → $13
Current: $1.44
Upside: +802.78%
Acelyrin
Apr 1, 2024
Reiterates: Buy
Price Target: $28
Current: $4.24
Upside: +560.38%
Femasys
Apr 1, 2024
Maintains: Buy
Price Target: $10 → $12
Current: $1.27
Upside: +844.88%
NovoCure
Mar 27, 2024
Maintains: Neutral
Price Target: $22 → $24
Current: $12.64
Upside: +89.95%
Nkarta
Mar 25, 2024
Maintains: Buy
Price Target: $20 → $22
Current: $6.87
Upside: +220.23%
NextCure
Mar 22, 2024
Maintains: Buy
Price Target: $5 → $8
Current: $1.35
Upside: +492.59%
Context Therapeutics
Mar 21, 2024
Maintains: Buy
Price Target: $5 → $4
Current: $1.41
Upside: +183.67%
MiNK Therapeutics
Mar 21, 2024
Maintains: Buy
Price Target: $10 → $9
Current: $0.93
Upside: +870.35%
Agenus
Mar 14, 2024
Maintains: Buy
Price Target: $160
Current: $11.69
Upside: +1,268.69%
Olema Pharmaceuticals
Mar 12, 2024
Maintains: Buy
Price Target: $28 → $25
Current: $9.95
Upside: +151.26%
IO Biotech
Mar 6, 2024
Reiterates: Buy
Price Target: $8
Current: $1.42
Upside: +463.38%
Sana Biotechnology
Mar 1, 2024
Reiterates: Buy
Price Target: $12
Current: $8.72
Upside: +37.61%
Arcellx
Feb 29, 2024
Maintains: Buy
Price Target: $60 → $82
Current: $51.92
Upside: +57.94%
BriaCell Therapeutics
Dec 28, 2023
Reiterates: Buy
Price Target: $18
Current: $2.23
Upside: +707.17%
Ventyx Biosciences
Nov 7, 2023
Downgrades: Neutral
Price Target: n/a
Current: $3.93
Upside: -